Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Azatiq

(Iberdomide)

Phase 3Small molecule

Bristol-Myers Squibb

Iberdomide is used to treat multiple myeloma, a type of blood cancer, often in combination with other medications. It works by helping the immune system fight cancer cells and preventing the cancer from growing.[1] Azatiq is currently being investigated across 10 indications[3], with its most advanced program in Phase 3.[1]

Azatiq is one of 232 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 3.

10

Indications

33

Total Trials

28

Active Trials

231

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

LymphomaActive, not recruiting

NeuroblastomaActive, not recruiting

SarcoidosisActive, not recruiting

Multiple MyelomaActive, not recruiting

Non-Hodgkin LymphomaRecruiting

Recurrent Multiple MyelomaRecruiting

Newly Diagnosed Multiple MyelomaRecruiting

Recurrent GanglioneuroblastomaNot yet recruiting

Renal InsufficiencyActive, not recruiting

Systemic Lupus ErythematosusPhase 2

Active, not recruiting

LymphomaPhase 1

Active, not recruiting

NeuroblastomaPhase 1/Phase 2

Active, not recruiting

SarcoidosisPhase 2

Active, not recruiting

Multiple MyelomaPhase 3

Active, not recruiting

Non-Hodgkin LymphomaPhase 1

Recruiting

Recurrent Multiple MyelomaPhase 1

Recruiting

Newly Diagnosed Multiple MyelomaPhase 3

Recruiting

Recurrent GanglioneuroblastomaPreclinical

Not yet recruiting

Renal InsufficiencyPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Azatiq

Bristol-Myers Squibb

Blenoxane

SSequus Pharmaceuticals

Oncaspar

Zofran

Wellcovorin

GGlaxo Dba Glaxosmithkline

Tafasitamab

Kenalog

BBausch Health Americas, Inc.

Decadron

QQuince Therapeutics S.p.A.

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

Bristol-Myers Squibb

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Active, not recruiting

MRD

NCT05434689

Phase 1Active, not recruiting

Multiple Myeloma

NCT05560399

Phase 1Recruiting

Recurrent Multiple Myeloma

NCT06465316

Q4 2027

Phase 2Recruiting

Multiple Myeloma

NCT06179888

Phase 2Active, not recruiting

Newly Diagnosed

NCT04564703

Q1 2028

Phase 1Recruiting

Multiple Myeloma

NCT06215118

Clinical

Trials by Indication[1]

Multiple Myeloma18 trials

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Recruiting· Pfizer logo

Pfizer·Phase 1·NCT06215118·87 enrolled

Iberdomide Maintenance Therapy in Patients With Multiple Myeloma

Active, not recruiting·UUniversity of Nebraska·Phase 2·NCT05177536·40 enrolled

Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

Recruiting· AbbVie logo

AbbVie·Phase 1·NCT06896916·135 enrolled

Show 15 more trials

Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05354557·16 enrolled

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

Active, not recruiting·MMayo Clinic·Phase 1/2·NCT05392946·49 enrolled

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06179888·78 enrolled

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting·—·Phase 2·NCT05896228·30 enrolled

A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Active, not recruiting·IIcahn School of Medicine at Mount Sinai·Phase 1·NCT05560399·7 enrolled

Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma

Recruiting·UUniversity of Heidelberg Medical Center·Phase 3·NCT06216158·411 enrolled

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 1·NCT06121843·147 enrolled

A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."

Active, not recruiting·NNantes University Hospital·Phase 2·NCT04998786·75 enrolled

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT04975997·864 enrolled

Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma

Terminated·IiTeos Therapeutics·Phase 1·NCT05289492·16 enrolled

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Recruiting·—·Phase 1·NCT06348108·32 enrolled

A Phase I/II Study of Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Patients With Newly Diagnosed Transplant Eligible Multiple Myeloma

Suspended·HHackensack Meridian Health·Preclinical·NCT05199311·66 enrolled

A Platform Study Evaluating the Safety and Efficacy of Multiple Treatments in Patients With Multiple Myeloma

Recruiting· Roche logo

Roche·Preclinical·NCT05583617·200 enrolled

A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplantation (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance)

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT05827016·1,230 enrolled

IBEX: Phase 2 Trial of Iberdomide + SQ Daratumumab as Post-Autologous Stem Cell Transplant Maintenance Therapy in Multiple Myeloma

Recruiting·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT06107738·60 enrolled

Recurrent Multiple Myeloma3 trials

A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination With Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma

Recruiting·AAlliance for Clinical Trials in Oncology·Preclinical·NCT06232044·88 enrolled

A Phase 1b Trial of Teclistamab in Combination With Iberdomide for Relapsed/Refractory Multiple Myeloma

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT06465316·26 enrolled

Phase 1/2 Trial of Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for Relapsed Multiple Myeloma

Recruiting·MMayo Clinic·Preclinical·NCT06785415·37 enrolled

Dexamethasone2 trials

Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients

Recruiting·CCanadian Myeloma Research Group·Phase 2·NCT05272826·75 enrolled

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Recruiting·—·Phase 1/2·NCT06518551·49 enrolled

Adult1 trial

A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT05899738·32 enrolled

Newly Diagnosed1 trial

Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients

Active, not recruiting·SStichting European Myeloma Network·Phase 2·NCT04564703·160 enrolled

8 more indications

MRD1 trial

COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide

Active, not recruiting·UUniversity of Alabama at Birmingham·Phase 1/2·NCT05434689·80 enrolled

Impairment1 trial

Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04933747·26 enrolled

ESS1 trial

Expanded Access for Iberdomide

Available· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT07434960

Newly Diagnosed Patients1 trial

Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.

Not yet recruiting·PPETHEMA Foundation·Phase 2·NCT05527340·140 enrolled

Smouldering Myeloma1 trial

Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma

Recruiting·UUniversity College, London·Phase 2·NCT06762769·63 enrolled

Non-Hodgkin Lymphoma1 trial

A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Patients With B-Cell Non-Hodgkin Lymphoma

Recruiting· Roche logo

Roche·Phase 1·NCT05169515·121 enrolled

Recurrent Ganglioneuroblastoma1 trial

Phase 1/2 Study of Dinutuximab/Cyclophosphamide/Topotecan/Sargramostim (GM-CSF) With or Without Iberdomide in Children With Relapsed, Refractory, or Progressive Neuroblastoma Following Prior Chemoimmunotherapy

Not yet recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT07437963·76 enrolled

Newly Diagnosed Multiple Myeloma1 trial

GEM21menos65. A Phase III Trial for NDMM Patients Who Are Candidates for ASCT Comparing Extended VRD Plus Early Rescue Intervention vs Isatuximab-VRD vs Isatuximab-V-Iberdomide-D

Recruiting·PPETHEMA Foundation·Phase 3·NCT05558319·480 enrolled

Sources

References

[1]
ClinicalTrials.gov — 33 trial records for Iberdomide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Iberdomide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Iberdomide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: CRL4(CRBN) E3 Ubiquitin Ligase Modulator[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bristol-Myers Squibb

Related News